Asahi Life Asset Management CO. LTD. Purchases 570 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Asahi Life Asset Management CO. LTD. grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 186.9% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 875 shares of the medical research company’s stock after purchasing an additional 570 shares during the quarter. Asahi Life Asset Management CO. LTD.’s holdings in Thermo Fisher Scientific were worth $464,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of TMO. Northwest Financial Advisors bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at $29,000. Cape Investment Advisory Inc. increased its stake in Thermo Fisher Scientific by 52.0% during the 4th quarter. Cape Investment Advisory Inc. now owns 76 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 26 shares in the last quarter. Raleigh Capital Management Inc. grew its stake in shares of Thermo Fisher Scientific by 49.1% in the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock worth $41,000 after acquiring an additional 27 shares in the last quarter. Cedar Mountain Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after acquiring an additional 46 shares in the last quarter. Finally, Frazier Financial Advisors LLC bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $49,000. Institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on TMO. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. HSBC increased their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday, April 25th. Evercore ISI increased their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $650.00 target price (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $607.94.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,000 shares of company stock valued at $18,512,580. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $1.25 during trading hours on Friday, hitting $581.09. 1,231,849 shares of the company’s stock were exchanged, compared to its average volume of 1,492,013. The company has a market capitalization of $221.81 billion, a PE ratio of 37.19, a PEG ratio of 2.68 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The business’s 50 day simple moving average is $575.14 and its 200-day simple moving average is $554.02. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Shareholders of record on Friday, June 14th will be given a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.